Canadian Amiodarone Myocardial Infarction Arrhythmia Trial (CAMIAT): rationale and protocol. CAMIAT Investigators.
The Canadian Amiodarone Myocardial Infarction Trial (CAMIAT) is a multicenter, triple-blind, randomized, placebo-controlled trial. Eligible patients are those found on 24-hour ambulatory electrocardiographic monitoring within 6-45 days of acute myocardial infarction to have ventricular premature depolarizations (VPDs) that are frequent (> or = 10/hr) or repetitive (> or = 1 three-beat run of ventricular tachycardia). Consenting patients are randomized to amiodarone or placebo with an oral loading dose of 10 mg/kg/day for 2 weeks; maintenance dose is 300-400 mg/day for 3.5 months, 200-300 mg/day for 4 months, and 200 mg/day for 5 or 7 days/week for 16 months. Patients are followed by alternate telephone and clinical visit at 2-month intervals for 24 months. The principal outcome is a composite of presumed arrhythmic death or resuscitated ventricular fibrillation. Outcomes are determined by an external validation committee. The anticipated rate of arrhythmic death is 7.5% over 2 years; the sample size is 1,200 patients. CAMIAT began in June 1990 and is anticipated to conclude enrollment by June 1994 and follow-up by June 1995. Recruitment rate is about 92% of projected.
Cairns
J A
JA
Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Connolly
S J
SJ
Roberts
R
R
Gent
M
M
D000638:Amiodarone / Q000627:therapeutic use*; D002170:Canada; D006801:Humans; D009203:Myocardial Infarction / Q000150:complications*; D010865:Pilot Projects; D016016:Proportional Hazards Models; D012107:Research Design; D013610:Tachycardia / Q000188:drug therapy* / Q000209:etiology; D016896:Treatment Outcome
D000638:Amiodarone